Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Core Viewpoint - Jaguar Health, Inc. has received a $240,000 grant from the U.S. Food and Drug Administration's Center for Veterinary Medicine for its product Canalevia-CA1, which is conditionally approved for treating chemotherapy-induced diarrhea in dogs [1]. Company Summary - The grant awarded to Jaguar Health, Inc. amounts to $240,000 [1]. - Canalevia-CA1 is currently conditionally approved for use in dogs suffering from chemotherapy-induced diarrhea [1].